Compare Amgen, Inc. (AMGN) vs Cintas Corporation (CTAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Cintas Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Cintas Corporation trades at $180.48 (market cap $71.88B). The key difference: Amgen, Inc. is far larger — about 2.7× Cintas Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CTAS | |
|---|---|---|
Market Cap | $196.12B | $71.88B |
Sector | Health | Industrials |
52-Week High | $388.16 | $226.27 |
52-Week Low | $271.18 | $163.55 |
Enterprise Value | $241.41B | $74.62B |
Dividend Yield | 2.77% | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Cintas (CTAS) trades at $179.64, up 1.1% on the day, with a bullish technical signal and strong fundamentals including 17.57% net margin and consistent revenue growth to $10.34B in 2025. The stock shows robust cash flow from operations at $2.17B and has beaten earnings estimates in recent quarters. Recent news highlights upcoming Q4 2026 earnings and recognition as a top workplace, supporting positive sentiment.
Outlook remains favorable with a consensus price target of $212.50, though high valuation multiples (P/E 37.9) and competitive pressures pose risks. Earnings growth and market share expansion are key catalysts, but investors should monitor debt levels and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
